 |
|
COMMENTS AND OPINIONS
Assessment of Delayed Reporting of Mycosis Fungoides and Sézary Syndrome in the United States
Graça M. Dores, MD, MPH;
Rochelle E. Curtis, MA;
William F. Anderson, MD, MPH;
Marie-France Demierre, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Using data from the Surveillance, Epidemiology and End Results Program (SEER), Criscione and Weinstock1 described increasing incidence rates (IRs) for cutaneous T-cell lymphoma (CTCL) in the United States. The authors speculate that IRs may be underestimated owing to possible underregistration and delayed reporting. Underregistration or underreporting is difficult to assess; however, delayed reporting can be evaluated in SEER.2-3 Delayed reporting refers to cases submitted by SEER to the National Cancer Institute (NCI) after an allowable ascertainment period. Before submitting data to NCI, SEER registries have a 2-year period to collect information on all newly diagnosed cancer cases. Cases collected after this 2-year ascertainment period are reported on subsequent data submissions, thereby resulting in revised estimates of IRs for the earlier time period.2
Herein, we assess delayed reporting of mycosis fungoides and Sézary syndrome . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases
Bradford et al.
Blood 2009;113:5064-5073.
ABSTRACT
| FULL TEXT
|
